Lead Product(s) : Omadacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Paratek Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the collaboration, Novasep and Paratek will manufacture NUZYRA® (omadacycline), an FDA-approved tetracycline-class, once-daily oral and intravenous antibiotic for the treatment of adults with CABP and acute bacterial skin and skin str...
Product Name : Nuzyra
Product Type : Antibiotic
Upfront Cash : Undisclosed
February 15, 2022
Lead Product(s) : Omadacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Paratek Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Monomethyl Auristatin E-conjugated Antibody
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : McSAF
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Novasep has successfully optimized and scaled-up the process of Adcitmer® (monomethyl auristatin E-conjugated antibody), McSAF Inside® Oncology’s first-in-class proprietary ADC to treat neuroendocrine cancers.
Product Name : Adcitmer
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
November 18, 2021
Lead Product(s) : Monomethyl Auristatin E-conjugated Antibody
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : McSAF
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Teriflunomide
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Breckenridge Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Breckenridge Announces Approval of its ANDA for Teriflunomide Tablets (generic for Aubagio)
Details : Aubagio-Generic (teriflunomide) is a USFDA approved pyrimidine synthesis inhibitor which is indicated for the treatment of patients with relapsing forms of multiple sclerosis.
Product Name : Aubagio-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 29, 2021
Lead Product(s) : Teriflunomide
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Breckenridge Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Novasep Secures Manufacturing Deal with US Biotech for ADC Drug Candidate
Details : Through the agreement, Novosep will perform the process development of the XB002 ADC. which is being evaluated in the early-stage clinical trial studies for the treatment of non-small cell lung cancer and cervical cancer.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
July 06, 2021
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Preclinical
Sponsor : Sensorion
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement aims for the manufacturing of adeno-associated virus (AAV) vectors, covering the gene therapy program targeting OTOF (OTOF-GT), the gene encoding the otoferlin protein and aims to restore the expression of Otoferlin.
Product Name : OTOF-GT
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
October 27, 2020
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Preclinical
Sponsor : Sensorion
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : LYS-GM101
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Lysogene
Deal Size : Undisclosed
Deal Type : Collaboration
Details : With this collaboration, the two companies consolidate their long-lasting partnership initiated with the development and manufacturing of Lysogene's lead gene therapy product, LYS-SAF302, currently in clinical phase 2/3.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
May 26, 2020
Lead Product(s) : LYS-GM101
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Lysogene
Deal Size : Undisclosed
Deal Type : Collaboration
KEY PRODUCTS
Reset All
Axplora is your partner of choice for complex APIs.